UBS Group’s Strongbridge Biopharma plc. SBBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-5,188
Closed -$11K 11413
2021
Q3
$11K Sell
5,188
-21,261
-80% -$49.5K ﹤0.01% 7969
2021
Q2
$79K Buy
26,449
+10,243
+63% +$27K ﹤0.01% 6065
2021
Q1
$45K Sell
16,206
-3,094
-16% -$9.34K ﹤0.01% 6671
2020
Q4
$46K Buy
19,300
+14,590
+310% +$35.1K ﹤0.01% 6274
2020
Q3
$10K Sell
4,710
-11,778
-71% -$39.7K ﹤0.01% 6891
2020
Q2
$63K Sell
16,488
-8,553
-34% -$25.6K ﹤0.01% 5685
2020
Q1
$47K Sell
25,041
-23,986
-49% -$62.3K ﹤0.01% 5889
2019
Q4
$102K Buy
49,027
+24,486
+100% +$46.9K ﹤0.01% 6002
2019
Q3
$59K Buy
24,541
+20,841
+563% +$56K ﹤0.01% 6108
2019
Q2
$12K Sell
3,700
-503
-12% -$1.85K ﹤0.01% 6978
2019
Q1
$21K Buy
4,203
+1,858
+79% +$9.15K ﹤0.01% 6294
2018
Q4
$11K Buy
2,345
+1,896
+422% +$9.26K ﹤0.01% 7209
2018
Q3
$2K Buy
+449
New +$2.3K ﹤0.01% 7780
2018
Q1
Sell
-264
Closed -$2K 8327
2017
Q4
$2K Sell
264
-2,576
-91% -$16.1K ﹤0.01% 7654
2017
Q3
$20K Buy
+2,840
New +$19.6K ﹤0.01% 6464
2016
Q4
Sell
-751
Closed -$4K 8157
2016
Q3
$4K Sell
751
-1,326
-64% -$5.98K ﹤0.01% 7227
2016
Q2
$8K Sell
2,077
-892
-30% -$4.21K ﹤0.01% 6921
2016
Q1
$14K Buy
2,969
+46
+2% +$207 ﹤0.01% 6462
2015
Q4
$22K Buy
+2,923
New +$21K ﹤0.01% 6672

UBS Group's SBBP Position: Q4 2021 in Review

UBS Group sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 5,188 shares — an estimated $11K sold.

UBS Group first reported a position in SBBP in Q4 2015 and held it in 19 quarters. The position peaked at $102K in Q4 2019. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.

  • UBS Group reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
  • UBS Group sold 5,188 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $11K.
  • UBS Group first reported a position in Strongbridge Biopharma plc. in Q4 2015 and held it in 19 quarters.
  • UBS Group's Strongbridge Biopharma plc. position peaked at $102K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.

Based on UBS Group's 13F filing for Q4 2021, filed 14 Feb 2022.